StreetInsider.com News Articles

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Sat, 13 Jun 2026 06:22:00 -0400

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Sat, 16 May 2026 03:18:00 -0400

The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection